HSA
ITCI

Hussman Strategic Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Hussman Strategic Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,500
Closed -$839K – 349
2023
Q1 		$839K Hold
15,500
– – 0.13% 233
2022
Q4 		$820K Hold
15,500
– – 0.13% 224
2022
Q3 		$721K Buy
+15,500
New +$810K 0.12% 234
2021
Q3 		– Sell
-31,000
Closed -$1.26M – 358
2021
Q2 		$1.26M Buy
+31,000
New +$1.15M 0.26% 155

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hussman Strategic Advisors's ITCI Position: Q2 2023 in Review

Hussman Strategic Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 15,500 shares — an estimated $839K sold.

Hussman Strategic Advisors first reported a position in ITCI in Q2 2021 and held it in 4 quarters. The position peaked at $1.26M in Q2 2021. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Hussman Strategic Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 15,500 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $839K.
  • Hussman Strategic Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 4 quarters.
  • Hussman Strategic Advisors's Intra-Cellular Therapies Inc. position peaked at $1.26M in Q2 2021.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Hussman Strategic Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.